Larimar Therapeutics, Inc.
New · 27 h live · Yahoo FinanceModerate buying: $382.1K bought (counted up to $5.0M); 7 distinct insiders. Holding it back: largest buyer: BEN-MAIMON CAROLE (CEO), 49% of the dollars.
AI summary Seven LRMR insiders, including the CEO, CFO, and President, bought $382,086 of stock in the open market after completing the nomlabofusp BLA submission.
Score, not a recommendation.
Price and insider purchases
Live chart from Yahoo Finance, loaded through this server; our daily closes when it is unavailable.
Loading price history…
How the score adds up
How each input is counted →| Input | Strength | Points |
|---|---|---|
| $382.1K bought (counted up to $5.0M)The dollars the insiders bought, a purchase reported jointly counted once, counted from $131. Each tenfold adds 12.4 points, up to $5.0M; more adds nothing. The bar is empty at $10.0K and full at $5.0M. | 59% | +43 |
| 7 distinct insidersHow many different insiders bought. Each extra insider adds less than the one before (the points follow the log of the count: 4.3 per doubling). The bar is full at 10 insiders. | 85% | +12 |
| A CEO among the buyersWhether the chief executive is among the buyers: 10.6 points when yes. | 100% | +11 |
| Stock 55% below its 1-year high (counted up to 30%)How far the stock had fallen from its highest close of the past year, at the close before the buying. Every 10% of fall adds 1.9 points. A fall beyond 30% adds nothing more. The bar is full at a 30% fall. | 100% | +5 |
| 1 days from first to last purchaseDays between the first and the last purchase. Each day takes off 0.11 points: buying close together keeps more. The bar is empty at 60 days. | 98% | +0 |
| Routine or plan purchases: 0% of the dollars | 100% | +0 |
| Largest buyer: BEN-MAIMON CAROLE (CEO), 49% of the dollars | 60% | -6 |
| Match scoreA score from 0 to 100 worked out from the dollars bought, the number of insiders, whether a CEO bought, how far the stock had fallen, how spread out the purchases were and how much came from one buyer. Its weights were calibrated on past clusters. It is the default ranking of the lists and it decides which clusters get the AI review. It describes the buying; it is not a forecast. | 65 | |
| AI adjustmentPoints added or taken off by a language model that reads the SEC filings and recent news about the cluster and classifies the buying (for example open market, plan or offering). It can be wrong, it is shown as its own line, and it is never used in past results. | +9 | |
| Insider ScoreThe number from 0 to 100 shown on each cluster and used to rank the lists. By default it is the match score, plus the points of the AI review when there is one. It describes the buying; it is not a forecast or a recommendation. | 74 | |
Why are they buying?
AI · discretionary · catalyst credible · documentedOn November 9, 2026, two days before the buying began, Larimar Therapeutics filed a Form 8-K and announced the completion of its rolling BLA submission to the FDA for accelerated approval of nomlabofusp in Friedreich's ataxia. The insiders likely bought to signal confidence following that regulatory milestone and after a sharp 63-day decline of 38.4%, even as the stock jumped 12.6% after the November 9 filing while remaining 54.8% below its 1-year high.
CEO Carole Ben-Maimon, CFO Michael Celano, President John B. Harlow Jr., and Director Joseph Truitt each made their first open-market purchase in three years, while Director Thomas Edward Hamilton bought $187,082 indirectly through Cure FA Foundation, Inc. No insider has sold shares in the past 90 days, and all seven buyers have recorded zero sales over the past three years.
Filing references and sources
- Form 4 (Shankar Gopi) (opens in a new tab)
- Form 4 (Celano Michael) (opens in a new tab)
- Form 4 (Harlow John B. Jr.) (opens in a new tab)
- Form 4 (Truitt Joseph) (opens in a new tab)
- Form 4 (THOMAS FRANK E) (opens in a new tab)
- Form 4 (BEN-MAIMON CAROLE) (opens in a new tab)
- Form 4 (Hamilton Thomas Edward) (opens in a new tab)
- Form 8-K (2026-11-09) (opens in a new tab)
- Exhibit 99.1 Press Release: Larimar Therapeutics Completes Rolling BLA Submission (opens in a new tab)
| Date | InsiderAn officer or director of a company, or an owner of more than 10% of its shares. The law requires them to report their trades in the company's stock to the SEC. | Role | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-11-12 | Hamilton Thomas Edward history of Hamilton Thomas Edward's purchases | Director | 70,000 | $2.67 | $187.1K | SEC filing for Hamilton Thomas Edward (opens in a new tab) |
| 2026-11-11 | Celano Michael history of Celano Michael's purchases | CFO | 18,460 | $2.71 | $50.0K | SEC filing for Celano Michael (opens in a new tab) |
| 2026-11-11 | BEN-MAIMON CAROLE history of BEN-MAIMON CAROLE's purchases | CEO | 18,050 | $2.77 | $50.0K | SEC filing for BEN-MAIMON CAROLE (opens in a new tab) |
| 2026-11-11 | Harlow John B. Jr. history of Harlow John B. Jr.'s purchases | President | 17,800 | $2.80 | $49.9K | SEC filing for Harlow John B. Jr. (opens in a new tab) |
| 2026-11-11 | THOMAS FRANK E history of THOMAS FRANK E's purchases | Director | 8,000 | $2.73 | $21.8K | SEC filing for THOMAS FRANK E (opens in a new tab) |
| 2026-11-11 | Shankar Gopi history of Shankar Gopi's purchases | Other C-suite | 5,000 | $2.71 | $13.5K | SEC filing for Shankar Gopi (opens in a new tab) |
| 2026-11-11 | Truitt Joseph history of Truitt Joseph's purchases | Director | 3,500 | $2.80 | $9.8K | SEC filing for Truitt Joseph (opens in a new tab) |
| Total | $382.1K | |||||
Other buying runs at LRMR
A buying runPurchases at one company with no pause longer than the cluster rule allows. A long pause ends the run, so one company can have several. ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmarkThe index a stock's return is compared with: a small-cap index for small companies, a large-cap index otherwise. (IWM for small companies, SPY otherwise), from the first open after the buying run became a cluster. Past results, not a forecast.
| Window | Insiders | Total | Score | 21 days vs benchmark | 63 days vs benchmark | 126 days vs benchmark | Status |
|---|---|---|---|---|---|---|---|
| 2026-02-27 | 4 | $25.6M | 40 | -13.5% (-16.1% raw) | -54.6% (-40.9% raw) | -43.0% (-29.4% raw) | closed |
| 2024-02-14 → 2024-02-16 | 3 | $25.5M | 51 | -7.5% (-10.0% raw) | -21.5% (-18.4% raw) | -44.1% (-26.9% raw) | closed |
| 2023-05-17 | 3 | $47.5K | 50 | -14.1% (-10.3% raw) | -1.5% (+2.1% raw) | -15.6% (-15.0% raw) | closed |
| 2022-09-16 | 4 | $9.9M | 70 | +5.8% (+2.1% raw) | +53.1% (+50.3% raw) | +32.2% (+29.2% raw) | closed |